A Bull's Eye for Targeted Lung Cancer Therapy-Reference-Cited by-同舟云学术

A Bull's Eye for Targeted Lung Cancer Therapy

Published:2004-06-04 Issue:5676 Volume:304 Page:1458-1461
ISSN:0036-8075
Container-title:Science
language:en
Short-container-title:Science

Author:

Minna John D.¹,Gazdar Adi F.¹,Sprang Stephen R.²,Herz Joachim²

Affiliation:

1. J. D. Minna is in the Departments of Internal Medicine and Pharmacology and A. F. Gazdar is in the Department of Pathology, Hamon Center for Therapeutic Oncology Research, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.

2. S. R. Sprang is in the Howard Hughes Medical Institute, Department of Biochemistry, and J. Herz is in the Department of Molecular Genetics, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.

Publisher

American Association for the Advancement of Science (AAAS)

Subject

Multidisciplinary

Reference7 articles.

1. Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib

2. EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy

3. Lung Cancer in US Women

4. Frederick L., et al., Cancer Res.60, 1383 (2000).

5. The role of EGFR inhibitors in nonsmall cell lung cancer

Cited by 70 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Molecular pathology of non‐small cell carcinoma;Histopathology;2023-11-07

2. Update Overview of the Role of Angiopoietins in Lung Cancer;Medicina;2021-11-01

3. Targeted methods for molecular characterization of EGFR mutational profile in lung cancer Moroccan cohort;Gene;2019-07

4. Prognostic value of angiopoietin-2 in non-small cell lung cancer patients: a meta-analysis;World Journal of Surgical Oncology;2016-09-02

5. Cancer modelling in the NGS era – Part I: Emerging technology and initial modelling;Critical Reviews in Oncology/Hematology;2015-11